Macrobid: profile and news

P&G Delivers 15% Earnings Per Share Growth for Fiscal Year  Aug 1, 2005
Product mix reduced sales by two percent due to strong oral care growth in developing markets and the shift of branded Macrobid® sales to generics. ... - Yahoo News (press release)

Ranbaxy gets USFDA nod for Macrobid®'s alternate  Mar 31, 2005
...to the BSE, USFDA has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid ... - Business Standard

Macrobid...Ranbaxy wins FDA nod to market its generic alternative  Mar 31, 2005
...from the US Food and Drug Administration to manufacture and market Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg, generic version of Macrobid. ... - India Infoline.com

P&G Delivers 15% EPS Growth - Raises Fiscal Year GuidanceStrong ...  Apr 28, 2005
Pricing added one percent to sales, while product mix reduced sales by one percent due to the shift of Macrobid(R) branded sales to generic sales and strong ... - mysan.de (Pressemitteilung)

US nod for Ranbaxy's antibiotic  Apr 1, 2005
...said that it had got approval from the US Food and Drug Administration to market a generic version of Procter and Gamble Co's antibiotic drug Macrobid capsules ... - Hindu Business Line

US nod for Ranbaxy's antibiotic  Apr 18, 2005
Laboratories has got approval from US Food and Drug Administration to market a generic version of Procter and Gamble Co‘s antibiotic drug Macrobid capsules. ... - Algorum

Ranbaxy Receives FDA Approval To Market A Generic Alternative To ...  Apr 2, 2005
Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid ... - Medical News Today

Ranbaxy Receives FDA Approval to Market a Generic Alternative to ...  Apr 1, 2005
...has determined the Ranbaxy formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid(R). Total annual ... - PR Newswire

Markets firm: Metal, oil stocks gain  Mar 31, 2005
Also biotech firms are to be exempt from requirement of compulsory license. Ranbaxy has received FDA approval to market a generic alternative to Macrobid. ... - Moneycontrol.com

Eon Labs Receives Final Approval for Nitrofurantoin Monohydrate ...  Apr 7, 2005
...announced that it received final approval today of Nitrofurantoin Monohydrate/Macrocrystals 100mg capsules, the generic equivalent to Macrobid(R)* capsules. ... - PharmaLive.com

Ranbaxy wins FDA approval, settles case  Apr 1, 2005
In a separate development, Ranbaxy has received USFDA approval to market a generic alternative to Macrobid, a drug indicated for the treatment of acute ... - Moneycontrol.com

Ranbaxy gets USFDA nod for new drug  Apr 1, 2005
The office of generic drugs, USFDA, determined the Ranbaxy formulations to be bioequivalent and having the same therapeutic effect as of Macrobid, a registered ... - Rediff

Ranbaxy-NHS settlement at £4.5 million  Apr 1, 2005
A generic alternative to Macrobid, a brand owned by Procter & Gamble Pharmaceuticals, this product has a market of $80 million in the US. - Financial Express

More Early Stocks in Motion  Apr 7, 2005
The company also said it received final approval for the generic version of the urinary tract treatment Macrobid, made by Proctor & Gamble (PG:NYSE ... - TheStreet.com

FDA approves Ranbaxy generic drug  Apr 1, 2005
...end of the month. The drug is a generic version of macrobid, which had annual sales of $80 million last year. "We are delighted ... - Jacksonville Business Journal,

Ranbaxy-NHS settlement at £4.5 million  08 Apr 2005
A generic alternative to Macrobid, a brand owned by Procter & Gamble Pharmaceuticals, this product has a market of $80 million in the US. - Express Pharma Pulse,

Eon Labs Receives Final Approval for Nitrofurantoin Monohydrate ...  08 Apr 2005
...announced that it received final approval today of Nitrofurantoin Monohydrate/Macrocrystals 100mg capsules, the generic equivalent to Macrobid(R)* capsules. ... - PharmaLive.com (press release),

Ranbaxy gets USFDA nod for Macrobid®'s alternate  Mar 31, 2005
...to the BSE, USFDA has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid ... - Business Standard,

Macrobid...Ranbaxy wins FDA nod to market its generic alternative  Mar 31, 2005
...from the US Food and Drug Administration to manufacture and market Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg, generic version of Macrobid. ... - India Infoline.com,

Ranbaxy Receives FDA Approval To Market A Generic Alternative To ...  Apr 2, 2005
Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid ... - Medical News Today,

Ranbaxy Receives FDA Approval to Market a Generic Alternative to ...  Apr 1, 2005
...has determined the Ranbaxy formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid(R). Total annual ... - PR Newswire (press release)

More Early Stocks in Motion  Apr 7, 2005
The company also said it received final approval for the generic version of the urinary tract treatment Macrobid, made by Proctor & Gamble (PG:NYSE ... - TheStreet.com

Markets firm: Metal, oil stocks gain  Mar 31, 2005
Also biotech firms are to be exempt from requirement of compulsory license. Ranbaxy has received FDA approval to market a generic alternative to Macrobid. ... - Moneycontrol.com,

Ranbaxy wins FDA approval, settles case  Apr 1, 2005
In a separate development, Ranbaxy has received USFDA approval to market a generic alternative to Macrobid, a drug indicated for the treatment of acute ... - Moneycontrol.com,

US nod for Ranbaxy's antibiotic  Apr 1, 2005
...said that it had got approval from the US Food and Drug Administration to market a generic version of Procter and Gamble Co's antibiotic drug Macrobid capsules ... - Hindu Business Line,

Ranbaxy gets USFDA nod for new drug  Apr 1, 2005
The office of generic drugs, USFDA, determined the Ranbaxy formulations to be bioequivalent and having the same therapeutic effect as of Macrobid, a registered ... - Rediff,

FDA approves Ranbaxy generic drug  Apr 1, 2005
...end of the month. The drug is a generic version of macrobid, which had annual sales of $80 million last year. "We are delighted ... - Jacksonville Business Journal,

Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.

Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.

Drug/Laboratory Test Interactions

As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedictís and Fehlingís solutions but not with the glucose enzymatic test.